Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting

Brian Seal, Sean D. Sullivan, Scott Ramsey, Carl V. Asche, Kenneth M Shermock, Syam Sarma, Erin Zagadailov, Eileen Farrelly, Michael Eaddy

Research output: Contribution to journalArticle

Abstract

Aim: To describe treatments and cost of care for prostate cancer (PCa) in hospital-based outpatient and inpatient settings. Methods: Hospital encounters associated with PCa (ICD-9 codes 185, 233.4) and PCa-related treatment in a hospital claims database were included. Results: There were 211,440 encounters for PCa between January 2006 and December 2010 (88,151 inpatient and 123,289 outpatient). Average cost per inpatient stay was US$12,286 versus US$4364 per outpatient visit. Most common treatment during an inpatient stay and outpatient visit was surgery (57%) and radiation (76%), respectively. A total of 80% of outpatient visits and 69.9% inpatient stays were associated with a single treatment; remaining encounters were associated with ≥2 treatments. Conclusion: Costs are consistent with previous estimates; however, multimodal therapy is an emerging trend that may be related to greater costs in the future which may also be a challenge for hospital decision makers.

Original languageEnglish (US)
Pages (from-to)439-447
Number of pages9
JournalFuture Oncology
Volume11
Issue number3
DOIs
StatePublished - Feb 1 2015

Fingerprint

Health Care Costs
Inpatients
Prostatic Neoplasms
Outpatients
International Classification of Diseases
Costs and Cost Analysis
Therapeutics
Cancer Care Facilities
Databases
Radiation

Keywords

  • healthcare costs/trends
  • hospitalization
  • prostatic neoplasms
  • retrospective studies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting. / Seal, Brian; Sullivan, Sean D.; Ramsey, Scott; Asche, Carl V.; Shermock, Kenneth M; Sarma, Syam; Zagadailov, Erin; Farrelly, Eileen; Eaddy, Michael.

In: Future Oncology, Vol. 11, No. 3, 01.02.2015, p. 439-447.

Research output: Contribution to journalArticle

Seal, B, Sullivan, SD, Ramsey, S, Asche, CV, Shermock, KM, Sarma, S, Zagadailov, E, Farrelly, E & Eaddy, M 2015, 'Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting', Future Oncology, vol. 11, no. 3, pp. 439-447. https://doi.org/10.2217/fon.14.242
Seal, Brian ; Sullivan, Sean D. ; Ramsey, Scott ; Asche, Carl V. ; Shermock, Kenneth M ; Sarma, Syam ; Zagadailov, Erin ; Farrelly, Eileen ; Eaddy, Michael. / Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting. In: Future Oncology. 2015 ; Vol. 11, No. 3. pp. 439-447.
@article{c3a31e7c29584a6c9959de9079e69254,
title = "Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting",
abstract = "Aim: To describe treatments and cost of care for prostate cancer (PCa) in hospital-based outpatient and inpatient settings. Methods: Hospital encounters associated with PCa (ICD-9 codes 185, 233.4) and PCa-related treatment in a hospital claims database were included. Results: There were 211,440 encounters for PCa between January 2006 and December 2010 (88,151 inpatient and 123,289 outpatient). Average cost per inpatient stay was US$12,286 versus US$4364 per outpatient visit. Most common treatment during an inpatient stay and outpatient visit was surgery (57{\%}) and radiation (76{\%}), respectively. A total of 80{\%} of outpatient visits and 69.9{\%} inpatient stays were associated with a single treatment; remaining encounters were associated with ≥2 treatments. Conclusion: Costs are consistent with previous estimates; however, multimodal therapy is an emerging trend that may be related to greater costs in the future which may also be a challenge for hospital decision makers.",
keywords = "healthcare costs/trends, hospitalization, prostatic neoplasms, retrospective studies",
author = "Brian Seal and Sullivan, {Sean D.} and Scott Ramsey and Asche, {Carl V.} and Shermock, {Kenneth M} and Syam Sarma and Erin Zagadailov and Eileen Farrelly and Michael Eaddy",
year = "2015",
month = "2",
day = "1",
doi = "10.2217/fon.14.242",
language = "English (US)",
volume = "11",
pages = "439--447",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting

AU - Seal, Brian

AU - Sullivan, Sean D.

AU - Ramsey, Scott

AU - Asche, Carl V.

AU - Shermock, Kenneth M

AU - Sarma, Syam

AU - Zagadailov, Erin

AU - Farrelly, Eileen

AU - Eaddy, Michael

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Aim: To describe treatments and cost of care for prostate cancer (PCa) in hospital-based outpatient and inpatient settings. Methods: Hospital encounters associated with PCa (ICD-9 codes 185, 233.4) and PCa-related treatment in a hospital claims database were included. Results: There were 211,440 encounters for PCa between January 2006 and December 2010 (88,151 inpatient and 123,289 outpatient). Average cost per inpatient stay was US$12,286 versus US$4364 per outpatient visit. Most common treatment during an inpatient stay and outpatient visit was surgery (57%) and radiation (76%), respectively. A total of 80% of outpatient visits and 69.9% inpatient stays were associated with a single treatment; remaining encounters were associated with ≥2 treatments. Conclusion: Costs are consistent with previous estimates; however, multimodal therapy is an emerging trend that may be related to greater costs in the future which may also be a challenge for hospital decision makers.

AB - Aim: To describe treatments and cost of care for prostate cancer (PCa) in hospital-based outpatient and inpatient settings. Methods: Hospital encounters associated with PCa (ICD-9 codes 185, 233.4) and PCa-related treatment in a hospital claims database were included. Results: There were 211,440 encounters for PCa between January 2006 and December 2010 (88,151 inpatient and 123,289 outpatient). Average cost per inpatient stay was US$12,286 versus US$4364 per outpatient visit. Most common treatment during an inpatient stay and outpatient visit was surgery (57%) and radiation (76%), respectively. A total of 80% of outpatient visits and 69.9% inpatient stays were associated with a single treatment; remaining encounters were associated with ≥2 treatments. Conclusion: Costs are consistent with previous estimates; however, multimodal therapy is an emerging trend that may be related to greater costs in the future which may also be a challenge for hospital decision makers.

KW - healthcare costs/trends

KW - hospitalization

KW - prostatic neoplasms

KW - retrospective studies

UR - http://www.scopus.com/inward/record.url?scp=84923095150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923095150&partnerID=8YFLogxK

U2 - 10.2217/fon.14.242

DO - 10.2217/fon.14.242

M3 - Article

C2 - 25675125

AN - SCOPUS:84923095150

VL - 11

SP - 439

EP - 447

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -